RESUMEN
BACKGROUND: The local application of growth factor provides a promising therapeutic strategy for the treatment of refractory bone defects. However, there are still many factors that limit the application of the local growth factor delivery system, for example, inability to accurately control the amount of growth factors released and the low biological activity of the released growth factors. OBJECTIVE: To summarize a variety of growth factor delivery systems containing extracellular matrix components and the latest research progress regarding their application in the treatment of bone defects. METHODS: The first authors searched PubMed, Web of Science, Medline, Wanfang and CNKI databases to retrieve articles published during 2007-2019 with the search terms “extracellular matrix, integrins, heparin, heparin, growth factor, controlled delivery system, bone defect” in English and Chinese, respectively. A total of 317 articles were initially retrieved, and 59 of them were included in the final analysis. RESULTS AND CONCLUSION: Extracellular matrix components can combine and regulate the activity of growth factors and improve their bioavailability. Therefore, improvement of growth factor delivery system can be achieved by integrating extracellular matrix components into the growth factor delivery system. Compared with the common growth factor delivery system, the extracellular matrix growth factor delivery system can obtain better growth factor binding effect, higher biological activity and utilization, and even better targeted release, thus producing better effects on promoting bone regeneration. Therefore, the extracellular matrix growth factor delivery system provides a better therapeutic strategy for local treatment of refractory bone defects.